The guidelines recommended that if an active TB infection was confirmed, TB therapy should be administered prior to initiating immunotherapy.[29] Furthermore, a reported case of nodular melanoma was found to have arisen from a trophic ulceration in a patient afflicted with leprosy.[30] After surgery, the patient received IFNα-2b immunotherapy, with no major side effects recorded. Here, IFNA2 is linked to nodular malignant melanoma.